Revised forecast
Fiscal year ending June 2026 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Due to the solid performance of equipment for genetic testing, increased sales of nucleic acid extraction reagents and related consumables as cumulative shipments grew, the effects of business reorganization and structural reform measures, a gain on the liquidation of a U.S. subsidiary, and the recognition of deferred tax assets.
| Item | Details |
|---|---|
| Net Sales | 660 |
| Operating profit | 339 |
| Ordinary income | 290 |
| Profit attributable to owners of the parent | 796 |
| Fiscal Period Covered | Fiscal year ending June 2026 |
| Period Covered | Full year |
| Previous-period results | Net sales ¥4,510 million, operating loss ¥122 million, ordinary loss ¥84 million, net loss ¥187 million, net loss per share ¥6.81 |
| Reason for the revision | Due to the solid performance of equipment for genetic testing, increased sales of nucleic acid extraction reagents and related consumables as cumulative shipments grew, the effects of business reorganization and structural reform measures, a gain on the liquidation of a U.S. subsidiary, and the recognition of deferred tax assets. |
| Consolidated / non-consolidated | Non-consolidated |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Equipment for genetic testing remained solid, and sales of nucleic acid extraction reagents and related consumables increased as cumulative shipments grew. Operating profit improved due to the effects of business reorganization and structural reform measures, while net income improved due to factors specific to the current fiscal year, including a gain on the liquidation of a U.S. subsidiary and the recognition of deferred tax assets.